|
1.
|
|
12 p, 615.6 KB |
ESMO Management and treatment adapted recommendations in the COVID-19 era : Breast Cancer
/
Azambuja, Evandro de (Institut Jules Bordet and l'Université Libre de Bruxelles) ;
Trapani, Dario (European Institute of Oncology) ;
Loibl, Sibylle (GBG Forschungs GmbH) ;
Delaloge, Suzette (Gustave Roussy and Paris-Saclay University) ;
Senkus, Elzbieta (Department of Oncology and Radiotherapy. Medical University of Gdańsk) ;
Criscitiello, Carmen (European Institute of Oncology) ;
Poortman, Philip (Iridium Kankernetwerk and University of Antwerp) ;
Gnant, Michael (Comprehensive Cancer Center. Medical University of Vienna) ;
Di Cosimo, Serena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Cortes Castan, Javier (Vall d'Hebron Institute d'Oncologia) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Paluch-Shimon, Shani (Shaare Zedek Medical Centre) ;
Curigliano, Giuseppe (Department of Oncology and Hemato-Oncology. University of Milano) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. [...]
2020 -  10.1136/esmoopen-2020-000793
ESMO Open, Vol. 5 (20 2020) , p. e000793
|
|
|
2.
|
|
14 p, 4.6 MB |
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
/
De Mattos-Arruda, Leticia (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ;
Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ;
Gonzalez-Cao, Maria (Hospital Universitari Quirón Dexeus) ;
Lim, Raymond S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
De Filippo, Maria R. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Fusco, Nicola (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Schultheis, Anne M. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Hospital Universitari Quirón Dexeus) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Macedo, Gabriel S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Teixidó, Cristina (Hospital Universitari Quirón Dexeus) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Vall d'Hebron Institut de Recerca) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Vall d'Hebron Institut de Recerca) ;
Tresserra Casas, Francesc (Hospital Universitari Quirón Dexeus) ;
Weigelt, Britta (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Cortes, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ;
Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630
|
|
|
3.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, S. (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y.H. (Experimental Therapeutics Group) ;
Gris-Oliver, Albert. (Experimental Therapeutics Group) ;
Bonache, S. (Oncogenetics Group) ;
Morancho, B. (Vall d'Hebron Institut d'Oncologia) ;
Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U.M. (Cancer Research UK. Cambridge Institute) ;
Jones, G.N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzman, M. (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, J. (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratú, G. (Cancer Genomics Group) ;
Mancuso, F. (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W.J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ;
Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J.C. (AstraZeneca (USA)) ;
Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ;
Baselga Torres, Josep, 1959-, (Memorial Sloan Kettering Cancer Center (USA)) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Jonkers, J. (Cancer Genomics Group) ;
Diez, Orland (Hospital Universitari Vall d'Hebron) ;
O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
|
4.
|
|
10 p, 3.3 MB |
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
/
Morancho, Beatriz (Hospital Universitari Vall d'Hebron) ;
Zacarías-Fluck, Mariano ;
Esgueva, Antonio (Hospital Universitari Vall d'Hebron) ;
Bernadó-Morales, Cristina (Hospital Universitari Vall d'Hebron) ;
Cosimo, Serena Di (Division of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy) ;
Prat, Aleix (Hospital Universitari Vall d'Hebron) ;
Cortés, Javier (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Rubio, Isabel T. (Hospital Universitari Vall d'Hebron)
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. [...]
2016 - 10.18632/oncotarget.11815
Oncotarget, Vol. 7 (september 2016) , p. 67956-67965
|
|
|
5.
|
|
14 p, 6.9 MB |
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
/
Hergueta-Redondo, Marta (Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain) ;
Sarrio, David (Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain) ;
Molina-Crespo, Ángela (Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain) ;
Vicario, Rocío (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bernadó-Morales, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez, Lidia (Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain) ;
Rojo-Sebastián, Alejandro (Pathology Department, MD Anderson Cancer Center, Madrid, Spain) ;
Serra-Musach, Jordi (Breast Cancer and Systems Biology Unit, ProCURE, Catalan Institute of Oncology, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain) ;
Mota, Alba (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ;
Martínez-Ramírez, Ángel (Cytogenetics Department, MD Anderson Cancer Center, Madrid, Spain) ;
Castilla, Maria Ángeles (Pathology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain) ;
González-Martin, Antonio (Oncology Department, MD Anderson Cancer Center, Madrid, Spain) ;
Pernas, Sonia (Breast Cancer and Systems Biology Unit, ProCURE, Catalan Institute of Oncology, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain) ;
Cano, Amparo (Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain) ;
Cortes, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Nuciforo, Paolo. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Palacios, José (Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain) ;
Pujana, Miguel Ángel (Breast Cancer and Systems Biology Unit, ProCURE, Catalan Institute of Oncology, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain) ;
Arribas, Joaquín (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno-Bueno, Gema (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. [...]
2016 - 10.18632/oncotarget.10787
Oncotarget, Vol. 7 (july 2016) , p. 56295-56308
|
|
|
6.
|
|
12 p, 2.2 MB |
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
/
De Mattos-Arruda, Leticia (Institut d'Oncologia de la Vall Hebron) ;
Bottai, Giulia (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Nuciforo, Paolo (Institut d'Oncologia de la Vall Hebron) ;
Di Tommaso, Luca (Division of Pathology. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Giovannetti, Elisa (University of Pisa. Cancer Pharmacology Laboratory. AIRC Start-Up Unit (Italy)) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Losurdo, Agnese (Division of Oncology and Hematology. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Pérez-Garcia, José (Institut d'Oncologia de la Vall Hebron) ;
Masci, Giovanna (Division of Oncology and Hematology. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Corsi, Fabio (University of Milan. Deparment of Clinical and Biomedical Sciences "Luigi Sacco" (Italy)) ;
Cortés, Javier (Hospital Universitario Ramón y Cajal) ;
Seoane Suárez, Joan (Institut d'Oncologia de la Vall Hebron) ;
Calin, George A. (The University of Texas MD Anderson Cancer Center (USA)) ;
Santarpia, Libero (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Universitat Autònoma de Barcelona
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies. Nevertheless, a significant proportion of these patients die of disease progression due to mechanisms of drug resistance. [...]
2015 - 10.18632/oncotarget.5495
Oncotarget, Vol. 6, Num. 35 (October 2015) , p. 37269-37280
|
|
|
7.
|
|
10 p, 1.9 MB |
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
/
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Thyparambil, Sheeno (OncoPlex Diagnostics. USA) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Garrido-Castro, Ana (Hospital Universitari Vall d'Hebron) ;
Vilaro, Marta (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Jimenez, José (Vall d'Hebron Institut d'Oncologia) ;
Vicario, Rocio (Vall d'Hebron Institut d'Oncologia) ;
Cecchi, Fabiola (OncoPlex Diagnostics. USA) ;
Hoos, William (OncoPlex Diagnostics. USA) ;
Burrows, Jon (OncoPlex Diagnostics. USA) ;
Hembrough, Todd (OncoPlex Diagnostics. USA) ;
Ferreres, Juan Carles (Hospital Universitari Vall d'Hebron) ;
Perez-Garcia, José (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V. (Vicente) (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ;
Cortes, Javier (Hospital Universitari Vall d'Hebron) ;
Scaltriti, Maurizio (Human Oncology & Pathogenesis Program (HOPP). Memorial Sloan-Kettering Cancer Center. USA) ;
Universitat Autònoma de Barcelona
Introduction: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments. [...]
2016 - 10.1016/j.molonc.2015.09.002
Molecular Oncology, Vol. 10, núm 1 (January 2016) , p. 138-147
|
|
|
8.
|
|
10 p, 426.6 KB |
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
/
Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Delord, J. P. (Institut Claudius Regaud (France)) ;
Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ;
Berge, Y. (Institut Claudius Regaud (France)) ;
Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ;
Cottura, E. (Institut Claudius Regaud (France)) ;
Bedard, P. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Akimov, M. (Novartis Pharma AG (Switzerland)) ;
Lu, H. (Novartis Pharmaceuticals Corp (USA)) ;
Pain, S. (Novartis Pharmaceuticals Corp (USA)) ;
Kaag, A. (Novartis Pharma AG (Switzerland)) ;
Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Cortés Castán, Javier (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659
|
|
|
9.
|
|
13 p, 297.5 KB |
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain : the CLEOPATRE study
/
Roura, Esther (Institut Germans Trias i Pujol) ;
Iftner, Thomas (Medical Virology, Section Experimental Virology, University Hospital of Tübingen, Tübingen, Germany) ;
Vidart, José Antonio (Gynaecology Department, Hospital Clínico San Carlos, Madrid, Spain) ;
Kjaer, Susanne Krüger (Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark) ;
Bosch, F Xavier (Institut Germans Trias i Pujol) ;
Muñoz, Nubia (Emeritus Professor at the National Cancer Institute, Bogotá, Colombia) ;
Palacios, Santiago (Instituto Palacios, Madrid, Spain) ;
Rodriguez, Maria San Martin (Medical Department, Sanofi Pasteur MSD, Madrid, Spain) ;
Morillo, Carmen (Medical Department, Sanofi Pasteur MSD, Madrid, Spain) ;
Serradell, Laurence (Epidemiology Department, Sanofi Pasteur MSD, Lyon, France) ;
Torcel-Pagnon, Laurence (Epidemiology Department, Sanofi Pasteur MSD, Lyon, France) ;
Cortes, Javier (Senior Consultant in Gynaecology Oncology, Spanish Society of Obstetrics and Gynaecology, Palma de Mallorca, Islas Baleares, Spain) ;
Castellsagué, Xavier (Institut Germans Trias i Pujol)
Human papillomavirus (HPV) is a sexually transmitted infection that may lead to development of precancerous and cancerous lesions of the cervix. The aim of the current study was to investigate socio-demographic, lifestyle, and medical factors for potential associations with cervical HPV infection in women undergoing cervical cancer screening in Spain. [...]
2012 - 10.1186/1471-2334-12-145
BMC Infectious diseases, Vol. 12 (june 2012) , p. 145
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
